ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.859,83
-0,04%
Brent Oil
82,765
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. TG Therapeutics Inc (TGTX)

  7. TG Therapeutics Inc (TGTX) Notícias

TGTX

TG Therapeutics (TGTX)

TG Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TGTX
DataHoraFonteTítuloCódigoCompanhia
01/05/202408:00GlobeNewswire Inc.TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:TGTXTG Therapeutics Inc
30/04/202417:55GlobeNewswire Inc.TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business UpdateNASDAQ:TGTXTG Therapeutics Inc
18/04/202408:30GlobeNewswire Inc.TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
18/04/202408:00GlobeNewswire Inc.TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple SclerosisNASDAQ:TGTXTG Therapeutics Inc
15/04/202408:30GlobeNewswire Inc.TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
08/03/202409:30GlobeNewswire Inc.TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
01/03/202409:30GlobeNewswire Inc.TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNASDAQ:TGTXTG Therapeutics Inc
29/02/202419:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TGTXTG Therapeutics Inc
28/02/202409:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TGTXTG Therapeutics Inc
28/02/202409:00GlobeNewswire Inc.TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:TGTXTG Therapeutics Inc
27/02/202409:30GlobeNewswire Inc.TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)NASDAQ:TGTXTG Therapeutics Inc
26/02/202409:00GlobeNewswire Inc.TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)NASDAQ:TGTXTG Therapeutics Inc
23/02/202409:30GlobeNewswire Inc.TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business UpdateNASDAQ:TGTXTG Therapeutics Inc
20/02/202409:30GlobeNewswire Inc.TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNASDAQ:TGTXTG Therapeutics Inc
14/02/202423:53Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
14/02/202417:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TGTXTG Therapeutics Inc
10/01/202409:00GlobeNewswire Inc.TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated MilestonesNASDAQ:TGTXTG Therapeutics Inc
09/01/202411:20AllPennyStocks.comBiotech Massively Bid Up Before Opening BellNASDAQ:TGTXTG Therapeutics Inc
09/01/202409:00GlobeNewswire Inc.TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune DiseasesNASDAQ:TGTXTG Therapeutics Inc
08/01/202420:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TGTXTG Therapeutics Inc
05/01/202413:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TGTXTG Therapeutics Inc
05/01/202409:30GlobeNewswire Inc.TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TGTXTG Therapeutics Inc
27/11/202309:30GlobeNewswire Inc.TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TGTXTG Therapeutics Inc
06/11/202319:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TGTXTG Therapeutics Inc
03/11/202308:30GlobeNewswire Inc.TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:TGTXTG Therapeutics Inc
01/11/202308:30GlobeNewswire Inc.TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:TGTXTG Therapeutics Inc
30/10/202308:30GlobeNewswire Inc.TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business UpdateNASDAQ:TGTXTG Therapeutics Inc
12/10/202312:00GlobeNewswire Inc.TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
02/10/202308:30GlobeNewswire Inc.TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingNASDAQ:TGTXTG Therapeutics Inc
22/09/202308:30GlobeNewswire Inc.TG Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:TGTXTG Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TGTX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZUL4
AZUL PN
BOV
GOLL4
GOL PN
BOV
HETA4
HERCULES PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados